Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Releases Earnings Results

Posted by Geri Gentry on Aug 14th, 2026

Calidi Biotherapeutics (NYSEAMERICAN:CLDI – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($2.94) earnings per share for the quarter, FiscalAI reports.

Calidi Biotherapeutics Trading Up 2.6%

CLDI stock traded up $0.04 during trading on Friday, hitting $1.58. The company had a trading volume of 110,068 shares, compared to its average volume of 228,684. The firm has a market capitalization of $1.91 million, a P/E ratio of -0.02 and a beta of 1.33. The company has a 50 day simple moving average of $2.15 and a 200-day simple moving average of $5.25. Calidi Biotherapeutics has a 52-week low of $1.48 and a 52-week high of $86.18. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.15.

Institutional Investors Weigh In On Calidi Biotherapeutics

Several large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of Calidi Biotherapeutics during the fourth quarter valued at about $25,000. Geode Capital Management LLC boosted its stake in Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after purchasing an additional 12,334 shares in the last quarter. Finally, DRW Securities LLC purchased a new stake in Calidi Biotherapeutics during the 4th quarter worth approximately $173,000. Institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

(Get Free Report)

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.